Welcome to our dedicated page for Zynex SEC filings (Ticker: ZYXI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zynex Inc. filings document the regulatory record of a medical technology company that develops and sells non-invasive devices for pain management, rehabilitation, and patient monitoring. Its periodic reports and current reports have covered operating results, liquidity, billing and reimbursement matters, compliance risks, governance changes, and material events affecting the company and its subsidiaries.
Recent filings also document Zynex's Chapter 11 reorganization and public-company status changes. The record includes 8-K disclosures on bankruptcy proceedings, plan amendments and confirmation, Nasdaq delisting and OTC trading status, material agreements with government authorities, the conclusion of an SEC investigation without a recommended enforcement action, and board actions. A Form 15 reports termination or suspension of Exchange Act registration duties after the plan became effective, the prior common stock was cancelled, and new common stock was issued to the plan sponsor.
Zynex, Inc. (ZYXI) filed a current report to announce that it released a press release with its financial results for the third quarter of 2025. The press release, dated November 17, 2025, is included as Exhibit 99.1 and is incorporated by reference into the report. The company states that the information in this item, including the press release, is being furnished rather than filed under securities law, which affects how related legal liabilities apply.
Zynex, Inc. filed a Form 12b-25 to notify a delay in its Form 10-Q for the quarter ended September 30, 2025. The company needs additional time to finalize the Q3 financial statements and related disclosures.
Management anticipates the upcoming Form 10-Q will disclose substantial doubt about the company’s ability to continue as a going concern, citing that current cash resources are not sufficient to support planned operations for at least 12 months from the expected issuance date of the Q3 financial statements.
Zynex expects to file the Form 10-Q within the five-day grace period allowed under Rule 12b-25.
Zynex, Inc. reported leadership changes tied to the resignation of Chief Commercial Officer Anna Lucsok. Her resignation was effective October 10, 2025, with separation terms finalized on October 27, 2025.
Under her employment agreement, Ms. Lucsok is entitled to severance, conditioned on her execution, non-revocation, and compliance with a Separation Agreement dated October 27, 2025. The Compensation Committee also approved the accelerated vesting of 60,746 unvested restricted shares previously issued to her, effective as of the Separation Date and subject to the same conditions.
Zynex, Inc. (ZYXI) reported a new director appointment disclosure. A Form 3 initial statement of beneficial ownership was filed indicating the reporting person is a Director and no securities are beneficially owned. The event date is 10/07/2025, and the filing was made by a single reporting person. This is a routine governance filing that establishes the insider’s baseline holdings at zero.
Zynex, Inc. appointed Bret W. Wise to its Board, expanding the board from five to six members effective October 7, 2025. Wise will serve until the 2026 annual meeting and was named Chair of the Audit Committee, and a member of the Compensation and Nominating and Governance Committees.
Director compensation: Wise will receive annual cash retainers of $40,000 (Board), $20,000 (Audit Chair), $7,500 (Compensation Committee), and $5,000 (Nominating and Governance), paid quarterly in arrears and pro‑rated as applicable. He will also receive an initial grant of 20,000 restricted shares and an annual grant of 10,000 restricted shares upon re‑election, vesting quarterly over three years, beginning one quarter after grant, subject to continued service.
Additional updates: Chair Thomas Sandgaard will receive annual retainers of $150,000 (Board Chair) and $250,000 (Technology Committee Chair), paid quarterly in arrears. Chief Commercial Officer Anna Lucsok resigned effective October 10, 2025.
Zynex, Inc. is making a strategic shift for its Zynex Monitoring Solutions (ZMS) business by seeking a commercialization partner for the NiCO™ CO-Oximeter instead of bringing the device to market on its own. As part of this change, the company terminated the positions of a majority of ZMS employees, with substantial cost savings expected from this reduction in force.
Zynex expects pre-tax cash charges of approximately $0.1 million for severance and pre-tax non-cash asset impairment charges of up to approximately $31.0 million, primarily related to goodwill and other assets associated with ZMS. Severance charges are expected to be recognized in the fourth quarter of 2025, and any impairment charges are expected to be recognized in the third quarter of 2025. The company notes there is no assurance it will succeed in attracting a commercialization partner for NiCO™.
Zynex, Inc. reported a leadership role change for one of its senior executives. Effective September 16, 2025, Anna Lucsok transitioned from serving as Chief Operating Officer to serving as the company’s Chief Commercial Officer. She will continue as an executive officer, meaning she remains part of the top management team. As part of this change, her prior responsibilities for overseeing manufacturing, information technology, and regulatory matters were re-allocated within the company to other areas or leaders. The filing does not describe changes to compensation or other terms, focusing instead on clarifying her new commercial-focused role.
Zynex, Inc. reported a leadership role change for one of its senior executives. Effective September 16, 2025, Anna Lucsok transitioned from serving as Chief Operating Officer to serving as the company’s Chief Commercial Officer. She will continue as an executive officer, meaning she remains part of the top management team. As part of this change, her prior responsibilities for overseeing manufacturing, information technology, and regulatory matters were re-allocated within the company to other areas or leaders. The filing does not describe changes to compensation or other terms, focusing instead on clarifying her new commercial-focused role.
Vikram Singh Bajaj filed an SEC Form 3 reporting his initial statement of beneficial ownership for Zynex Inc (ZYXI). The reported event date is 08/18/2025. Mr. Bajaj is identified as an officer with the title Chief Financial Officer. The form states no securities are beneficially owned by the reporting person at the time of filing. The form was signed on 09/03/2025.
Steven Lewis Dyson is reported as both Chief Executive Officer and a director of Zynex Inc (ZYXI) on an initial Form 3. The filing discloses that no securities are beneficially owned by the reporting person and that the Form was filed by a single reporting person. The form shows no non‑derivative or derivative holdings and includes the reporting person’s address.
John T. Bibb, listed as both a Director and the company's Chief Legal Officer, filed an Initial Statement of Beneficial Ownership (Form 3) for Zynex Inc (ZYXI) reporting the event date 08/18/2025. The filing explicitly states that no securities are beneficially owned by the reporting person. The form is signed and dated 08/28/2025.